Adicet Bio (ACET) vs Mereo BioPharma Group (MREO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adicet Bio (ACET) has outperformed Mereo BioPharma Group (MREO) over the past year, losing 61.4% versus a loss of 80.9%. Over five years, MREO leads with a -82.8% price change compared with -95.5% for ACET. Mereo BioPharma Group is the larger company by market cap ($55.3 million vs $53.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | MREO |
|---|---|---|
| Share price | $5.66 | $0.3465 |
| Market cap | $52.99M | $55.33M |
| 1-day change | -1.39% | -7.64% |
| YTD return | -31.83% | -10.02% |
| 1-year return | -61.38% | -80.86% |
| 5-year return | -95.54% | -82.79% |
| EPS (TTM) | $-10.42 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.44 | $2.37 |
| 52-week low | $5.55 | $0.20 |
| Distance from 52-week high | -67.55% | -85.38% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +515.37% | +465.66% |
| Average volume | 172.38K | 4.04M |
| Shares outstanding | 9.36M | 159.69M |
| Employees | 102 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACET has outperformed MREO by 19.5 percentage points over the past year.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
About Mereo BioPharma Group
MREO stock →Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
ACET vs MREO FAQ
Which is bigger, Adicet Bio or Mereo BioPharma Group?
Mereo BioPharma Group (MREO) is larger, with a market capitalization of $55.33M compared with $52.99M for Adicet Bio (ACET).
Which stock has performed better over the past year, ACET or MREO?
ACET returned -61.38% over the past 12 months, compared with -80.86% for MREO (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and Mereo BioPharma Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.